Rafferty Asset Management, LLC Pro Qr Therapeutics N.V. Transaction History

Rafferty Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.99 - $3.66 $43,143 - $79,348	21,680 New	21,680 $46,000
Q2 2022 Aug 12, 2022	SELL	$0.56 - $1.0 $169,879 - $303,356	-303,356 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$0.9 - $8.39 $34,854 - $324,919	-38,727 Reduced 11.32%	303,356 $275,000
Q4 2021 Feb 10, 2022	SELL	$6.58 - $8.44 $1.24 Million - $1.59 Million	-187,800 Reduced 35.44%	342,083 $2.74 Million
Q3 2021 Nov 10, 2021	SELL	$5.16 - $8.47 $288,562 - $473,667	-55,923 Reduced 9.55%	529,883 $4.44 Million
Q2 2021 Aug 10, 2021	BUY	$5.75 - $7.59 $3.37 Million - $4.45 Million	585,806 New	585,806 $3.95 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.